Respiratory syncytial virus (RSV) causes serious respiratory illness in preterm children with bronchopulmonary dysplasia. In a prospective randomized placebo-controlled trial, 21 children received one dose of PFP-2 (purified fusion [F] protein) vaccine or influenza vaccine (placebo). Children were followed for adverse reactions and RSV illness over two respiratory seasons. Sera were obtained for determination of IgG titers to RSV F protein and neutralizing antibody titers before and 1, 6, and 12 months after vaccination. Adverse reactions were few. Four-fold F protein rises occurred in 9 of 10 PFP-2 and 0 of 11 placebo recipients. Six PFP-2 recipients had low prevaccination neutralizing antibody titers (õ1:450); all had 4-fold rises. By 12 months, F protein and neutralizing antibody titers in all 21 children were similar. RSV illness occurred in 6 of 11 placebo versus 1 of 10 PFP-2 recipients (P Å .06); 1 placebo child required hospitalization. PFP-2 vaccine appears safe and immunogenic and may protect children with bronchopulmonary dysplasia against serious RSV disease on reinfection.
Respiratory syncytial virus (RSV) has been recognized as
Methods an important pediatric respiratory pathogen for ú4 decades Study population. Children ú12 months of age with broncho- [1 -3] . In certain high-risk populations, RSV reinfection may pulmonary dysplasia were the subjects of this study. Bronchopulalso cause serious illness. Infants and young children with monary dysplasia was defined as chronic lung disease occurring bronchopulmonary dysplasia, the chronic lung disease of preas a result of premature delivery and ventilatory support and an term ventilated infants, constitute one of the largest populations ongoing oxygen requirement of at least 1 month's duration [4] . All at risk for recurrent severe RSV disease [4, 5] . There are no children had had culture-or serologically proven RSV infections in safe and effective vaccines currently available for very young a previous respiratory season. All had received influenza vaccinainfants. The severe pulmonary disease on primary RSV infection in the previous year. All study subjects were followed as tion in infants who received RSV formalin vaccine [6, 7] neutralizing antibody that protects against RSV lower respiraused for all study children in a single season. All study children tory tract infection [12] . The purpose of this study was to also received an unblinded dose of trivalent influenza vaccine 4-assess the safety, immunogenicity, and efficacy of an improved Concise Communications JID 1998; 177 (February) were evaluated within 24 h by a physician. A nasal wash specimen titers (õ1:450 ú99.9% F glycoprotein, has been demonstrated to be safe and was measured by use of a microneutralization assay also described immunogenic in seropositive children with cystic fibrosis [10] .
previously [12] .
The present trial demonstrates the safety and immunogenicity of the PFP-2 vaccine in a seropositive population of infants with bronchopulmonary dysplasia prospectively observed over Results two respiratory seasons. Immediate adverse vaccine reactions were minimal, and enhanced RSV illness in a subsequent seaTwenty-one children participated in this study. Ten children received PFP-2 and 11 received the trivalent influenza vaccine son was not observed. Four-fold F protein antibody titer rises occurred in all PFP-2 recipients. The highest RSV neutralizing as placebo. Mean age at study entry (32.2 vs. 30.0 months), sex, race, previous RSV hospitalizations, day care exposure, antibody responses were observed primarily in those PFP-2 vaccine recipients with low prevaccination titers (õ1:450). passive smoke exposure, and number of siblings in the home were comparable between groups.
This finding is comparable to observations in elderly people [14] . The finding that suboptimal RSV neutralizing antibody Safety. Adverse reactions were few. Systemic acute reactions included irritability (2 infants in the PFP-2 group, 2 in titers can be boosted has important clinical relevance, since high RSV neutralizing antibody titers (ú1:400) are required the placebo group) and drowsiness (1 infant in the PFP-2 group). Local reactions included pain and tenderness (1 patient to protect the lower airway from RSV replication and infection [12, 13] . Several placebo recipients also developed elevated in each group) and redness (1 patient in the PFP-2 group). No child developed evidence of enhanced illness on RSV reinfec-RSV neutralizing antibody titers. This suggests that some antibody rise could have occurred following natural infection. Only tion during a follow-up respiratory season. The number and severity of RSV infections that occurred in the 21 study sub-1 PFP-2 vaccine recipient developed clinical RSV illness, however, compared with 6 placebo recipients (10% vs. 55%). While jects during the subsequent respiratory season were tabulated. Six placebo recipients developed clinical RSV infection comthe population studied in this trial was small, the trend toward efficacy is encouraging. These findings should encourage the pared with only 1 PFP-2 recipient (P Å .06, Fisher's twotailed test). The placebo group comprised 4 patients with upper implementation of larger studies to further assess safety and efficacy with PFP-2 vaccine in populations who are at risk for respiratory tract infections (respiratory score, 1), 1 child with mild lower respiratory infection (respiratory score, 2), and 1 severe recurrent RSV illness. Children with higher RSV neutralizing antibody titers before child who developed moderate lower respiratory infection (respiratory score, 3) and required hospitalization. The single PFP-PFP-2 vaccination maintained protective titers throughout the study. Persistence of antibody was observed in some placebo 2 recipient, who was RSV-positive, presented with mild lower respiratory infection (respiratory score, 2).
recipients, suggesting that intercurrent RSV infection may have naturally boosted some children. Only 10% (1/10) of PFP-2 Immunogenicity. Table 1 summarizes the F glycoproteinspecific and neutralizing antibody titers in all 21 study patients.
recipients developed RSV illness, compared with 55% (6/11) of placebo recipients. The sample size is too small to assess Four-fold immune responses to F protein antibody were observed in 9 of 10 PFP-2 recipients and 0 of 11 placebo recipisignificance; however, these findings should encourage [4, 5] larger studies with PFP-2 vaccine in populations of children ents. Four-fold RSV neutralizing antibody responses occurred primarily in 6 PFP-2 recipients with low prevaccination RSV who are at risk for severe recurrent RSV illness.
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